Monoclonal proteins in chronic lymphocytic leukemia

P. Noel, R. A. Kyle

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

One hundred patients with chronic lymphocytic leukemia and a monoclonal protein in serum or urine were recognized during the period January 1971 to July 1984. IgG monoclonal proteins predominated, with the following distribution: IgG κ 36% (0.36), IgG λ 15% (0.15), IgM κ 27% (0.27), IgM λ 11% (0.11), IgA λ 1% (0.01), and free monoclonal light chains in 10% (0.10) (κ in 8% [0.08] and λ in 2% [0.02]). The median concentration of M-protein was 1.0 g/dL (10/gL) or less. The median survival (Kaplan-Meier) for the 100 patients after recognition of an M-protein was six years. The median survival was longer for patients with an IgG monoclonal protein (7.2 years) than for patients with an IgM monoclonal protein (5.2 years), although the difference was not significant. The authors found no important differences in patients with chronic lymphocytic leukemia, whether they had an IgG or an IgM monoclonal protein or a free monoclonal light chain.

Original languageEnglish (US)
Pages (from-to)385-388
Number of pages4
JournalAmerican journal of clinical pathology
Volume87
Issue number3
DOIs
StatePublished - 1987

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'Monoclonal proteins in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this